April 14, 2026

A pill once thought to be science fiction just smashed expectations in one of the deadliest cancers, and the numbers are brutal for the old guard: Revolution Medicines says daraxonrasib nearly doubled survival in late-stage pancreatic cancer, with patients living a median 13.2 months versus 6.7 months on standard chemotherapy, while cutting the risk of death by 60% and hitting every main and secondary goal in patients whose disease had already worsened after other treatment. One doctor called the results “truly transformational,” CEO Mark Goldsmith called them “practice-changing,” and the company is now racing to the FDA with a priority voucher that could speed approval by months. The drug targets RAS mutations, the engine behind about 90% of pancreatic cancers, long dubbed “undruggable,” and though a rash is a common side effect, doctors say it’s usually manageable. With pancreatic cancer still carrying a grim 13% five-year survival rate, investors piled in fast, sending Revolution’s shares up more than 30% and lifting its market value above $26 billion.

Leave a Reply